The pharmacokinetics of etanercept in healthy volunteers

被引:1
|
作者
Korth-Bradley, JM
Rubin, AS
Hanna, RK
Simcoe, DK
Lebsack, ME
机构
[1] Wyeth Ayerst Res, Clin Pharmacokinet, Philadelphia, PA 19101 USA
[2] Immunex Corp, Biometr, Seattle, WA 98101 USA
[3] Immunex Corp, Analyt Resources Dept, Seattle, WA 98101 USA
关键词
phamacokinetics; etanercept;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: TO describe the pharmacokinetics of etanercept when administered by subcutaneous injection in single doses to healthy volunteers, METHODS: Twenty-six healthy volunteers between 19 and 50 years of age received single doses of etanercept 25 mg by subcutaneous injection into the abdomen. Serial serum samples were collected for 21 days. An enzyme-linked immunosorbent assay with a quantitation limit of 0.3 ng/mL was used to measure the drug concentrations. RESULTS: Etanercept was well tolerated by healthy volunteers. A one-compartment model was found to best describe the concentration-time data and was used to determine the pharmacokinetic parameters. Etanercept is slowly absorbed from the site of injection with a time of peak concentration (+/- SD) of 51 +/- 14 hours; peak concentration was 1.46 +/- 0.72 mg/L. The AUC was 235 +/- 98 mg.h/L, apparent clearance was 132 +/- 85 mL/h, apparent volume of distribution was 12 +/- 6 L, and the half-life was 68 +/- 19 hours. CONCLUSIONS: Etanercept was slowly absorbed and slowly eliminated after subcutaneous administration. Dosing at the recommended rate of 25 mg twice weekly would be expected to result in concentrations of approximately 3 mg/L. Intersubject variability for apparent clearance in healthy volunteers was 64%.
引用
收藏
页码:161 / 164
页数:4
相关论文
共 50 条
  • [31] A randomized phase I pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects
    Lee, Yoon Jung
    Shin, Donghoon
    Kim, Youngdoe
    Kang, Jungwon
    Gauliard, Anke
    Fuhr, Rainard
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (01) : 64 - 73
  • [32] Etanercept in juvenile psoriasis
    Beikert, F. C.
    Augustin, M.
    Radtke, M. A.
    HAUTARZT, 2012, 63 (05): : 406 - 410
  • [33] Etanercept in psoriatic arthritis
    Anandarajah, AP
    Ritchlin, CT
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2003, 3 (01) : 169 - 177
  • [34] Etanercept in childhood psoriasis
    Perez-Barrio, S.
    Careaga, J. M.
    ACTAS DERMO-SIFILIOGRAFICAS, 2010, 101 : 50 - 54
  • [35] Etanercept monotherapy in psoriasis
    Christopher T. Ritchlin
    Current Rheumatology Reports, 2004, 6 (4) : 290 - 291
  • [36] Etanercept in the treatment of vitiligo
    Rigopoulos, Dimitris
    Gregoriou, Stamatis
    Larios, George
    Moustou, Evi
    Belayeva-Karatza, Elena
    Kalogeromitros, Dimitris
    DERMATOLOGY, 2007, 215 (01) : 84 - 85
  • [37] Rosacea associated with etanercept
    Yazici, Ayten
    Akturk, Aysun Sikar
    Cefle, Ayse
    Bayramgurler, Dilek
    Yildiz, Kursat Demir
    JOINT BONE SPINE, 2014, 81 (03) : 274 - 275
  • [38] Etanercept: Efficacy and safety
    Jimenez-Puya, R.
    Gomez-Garcia, F.
    Amorrich-Campos, V.
    Moreno-Gimenez, J. C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 (04) : 402 - 405
  • [39] Scleritis: A Paradoxical Effect of Etanercept? Etanercept-associated Inflammatory Eye Disease
    Gaujoux-Viala, Cecile
    Giampietro, Cecilia
    Gaujoux, Thomas
    Ea, Hang-Korng
    Prati, Clement
    Orcel, Philippe
    Wendling, Daniel
    Liote, Frederic
    JOURNAL OF RHEUMATOLOGY, 2012, 39 (02) : 233 - 239
  • [40] Etanercept in Psoriatic Arthritis
    Spadaro, Antonio
    Lubrano, Ennio
    Ferrara, Nicola
    Scarpa, Raffaele
    JOURNAL OF RHEUMATOLOGY, 2012, 39 : 74 - 76